The embedded training and coaching AI strengthen human-led delivery, especially for complex customer, member and ...

DUBLIN, Ireland and CHICAGO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company or Iterum), a company focused on delivering next generation oral and IV antibiotics ...

Iterum Therapeutics plc announced the publication of results from its Phase 3 clinical trial, REASSURE, in NEJM Evidence, which evaluated the efficacy of oral sulopenem compared to Augmentin® in ...

Iterum Therapeutics (ITRM) provided a general business update. ORLYNVAH Launch Update: In partnership with EVERSANA Life Science Services, ORLYNVAH was launched in August 2025 into the community ...

--FDA correspondence regarding the use of ORLYNVAH™ as step-down therapy DUBLIN and CHICAGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we” ...

Iterum Therapeutics set terms Tuesday for its initial public offering, in which the drugmaker could raise up to $85.3 million. The company, which is developing sulopenem antibiotic that could ...

DUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the "Company” or "Iterum”), a company focused on delivering next generation oral and IV antibiotics to ...

Iterum Therapeutics plc announced that it has partnered with EVERSANA Life Science Services to commercialize its approved product, ORLYNVAHTM, the first oral penem antibiotic in the U.S., aiming for a ...

FDA-approved antibiotic with the power of a penem in a novel oral formulation, offering a vital alternative in treating uncomplicated urinary tract infections Sixty percent of women experience a ...

Iterum had hoped to win FDA approval for sulopenem etzadroxil/probenecid this month. The agency previously assigned a Prescription Drug User Fee Act (PDUFA) date of July 25 for the completion of its ...

DUBLIN and CHICAGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV ...